Señales en vivo de ATE.TO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 abr 2024 @ 15:59):

Stats
Volumen de hoy	167 044
Volumen promedio	131 837
Capitalización de mercado	15.53M
EPS	$0 ( 2024-02-12 )
Próxima fecha de ganancias	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.00700 (2.37%)

ANTIBE THERAPEUTICS INC Correlación

10 Correlaciones Más Positivas
SPG.TO	0.852
HPS-A.TO	0.843
PHYS.TO	0.841
XSQ.TO	0.841
TD-PFK.TO	0.812
AKU.TO	0.811

10 Correlaciones Más Negativas
ECN-PC.TO	-0.848

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ANTIBE THERAPEUTICS INC Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.370

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.370

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.490

FY	2021
Ingresos:	$9.71M
Beneficio Bruto:	$3.55M (36.55 %)
EPS:	$-0.700

Financial Reports:

No articles found.

ANTIBE THERAPEUTICS INC

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.